Overview


According to FutureWise analysis the market for haemostatic agents in 2023 is US$ 7.29 billion, and is expected to reach US$ 14.54 billion by 2031 at a CAGR of 9.02%.

Hemostasis Agents are on the rise because chronic diseases affect an aging population more frequently. As the number of surgical operations increases worldwide, the market for hemostasis agents will grow. Hemostasis is a process of stopping bleeding or blood flow through a blood vessel, or hemorrhage. Hemostasis occurs when a clot forms at the injured area, thus repairing the blood vessel. Hemostatic agents have been used to slow blood flow by promoting clotting and thereby improving hemostasis by accelerating the coagulation process. These agents enhance hemostasis by increasing fibrin production, inhibiting fibrinolysis, or advancing primary hemostasis. The role of hemostatic agents in the treatment or prevention of bleeding makes them important in a number of therapeutic fields. Defining hemostasis as the process of preventing blood loss into blood vessels, also known as hemorrhage. In hemostasis, a clot forms at the damaged site, causing the blood vessel to heal. Hemostasis includes primary hemostasis, secondary hemostasis, and fibrinolysis. In a blood vessel injury, platelets clump together to form a plug-in case. As a result of the association of clotting factors, a fibrin mesh is created that keeps the platelets in place. As a result, the injury heals and blood does not escape from the blood vessel. Blood flow is stopped by hemostatic agents that increase clotting and, in turn, increase hemostasis by speeding up the coagulation process.
These agents increase hemostasis by promoting primary hemostasis, increasing fibrin production, and inhibiting fibrinolysis. As a result of the increasing prevalence of chronic diseases among geriatrics, hemostasis agents are in demand. As surgical procedures increase worldwide, the global market for hemostasis agents will grow as a result.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Haemostatic Agents Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Haemostatic Agents Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Baxter
  • Ethicon US, LLC.
  • C. R. Bard, Inc.
  • B. Braun Melsungen AG
  • Pfizer Inc.
  • Z-Medica, LLC.
  • CryoLife, Inc.
  • Integra LifeSciences
  • Advanced Medical Solutions Group plc
  • GELITA AG

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Product Type

  • Active Agents
  • Passive Agents
  • Combination

By Specialty and Therapeutic Area

  • Cardiology
  • Cath Lab
  • Trauma
  • General Surgery
  • ObGyn
  • Transplant
  • Oncology
  • Neurology
  • Orthopedic
  • Plastic Surgery
  • Dental
  • Others (Urological Surgeries, Pulmonary Surgeries)

By Size of Hospitals

  • Large Hospitals (500+ bed size)
  • Medium Hospital (250-499 beds)
  • Small Hospitals (less than 250 beds)

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Haemostatic Agents Market By Product Type, By Specialty and Therapeutic Area, By Size of Hospitals and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Haemostatic Agents Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Haemostatic Agents Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Haemostatic Agents Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Haemostatic Agents Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Active Agents
        2. Passive Agents
        3. Combination

  • 8.   Haemostatic Agents Market, By Specialty and Therapeutic Area Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Cardiology
        2. Cath Lab
        3. Trauma
        4. General Surgery
        5. ObGyn
        6. Transplant
        7. Oncology
        8. Neurology
        9. Orthopedic
        10. Plastic Surgery
        11. Dental
        12. Others (Urological Surgeries, Pulmonary Surgeries)

  • 9.   Haemostatic Agents Market, By Size of Hospitals Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Large Hospitals (500+ bed size)
        2. Medium Hospital (250-499 beds)
        3. Small Hospitals (less than 250 beds)

  • 10.   North America Haemostatic Agents Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Haemostatic Agents Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Haemostatic Agents Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Haemostatic Agents Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Baxter
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Ethicon US, LLC.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. C. R. Bard, Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. B. Braun Melsungen AG
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Pfizer Inc.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Z-Medica, LLC.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. CryoLife, Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Integra LifeSciences
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Advanced Medical Solutions Group plc
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. GELITA AG
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients